Xbrane Gets Action Date As Ranibizumab Filing Accepted By FDA
Gains BsUFA Goal Date Of 21 April 2024 For Biosimilar Rival To Lucentis
Xbrane has announced the formal acceptance by the US FDA of its re-filed ranibizumab biosimilar, developed in collaboration with Stada and licensed in North America to Bausch + Lomb.
